Illumina, Inc. vs Standard Lithium Ltd — how do they compare? Illumina, Inc. trades at $264.95 (market cap $39.95B), while Standard Lithium Ltd trades at $1.61 (market cap $398.07M). The key difference: Illumina, Inc. is far larger — about 100.4× Standard Lithium Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Standard Lithium Ltd for 23 Days on average.
| ILMN | SLI | |
|---|---|---|
Market Cap | $39.95B | $398.07M |
Volume | 3,169,503 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $293.69 | $5.65 |
52-Week Low | $91.00 | $1.61 |
Typical Hold Time | 83 Days | 23 Days |
Enterprise Value | $41.31B | $260.98M |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE of -15.55% and ROA of -14.17%, though recent quarterly EPS beat expectations. Positive developments include progress toward a 2026 final investment decision for the Arkansas lithium project and expanded offtake agreements. Cash flow remains supported by financing activities despite negative operational cash flow.
The investment case hinges on successful project execution and lithium market dynamics. Analysts are unanimously bullish with a $3.83 price target, representing significant upside. Key risks include execution delays, negative cash flow, and commodity price volatility. The stock offers high-risk, high-reward exposure to North American lithium production growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →